title: [Influence Mildrocard on the morfo-functional condition of cardio-respiratory system at patients with chronic heart failure with concomitant chronic obstructive pulmonary disease].
abstract: In paper influence of a cytoprotective drug "Mildrocard" on morfo-functional condition of cardiorespiratory system at patients with chronic heart failure with concomitant chronic obstructive pulmonary disease is estimated. It is established, that joining "Mildrocard" to complex therapy associated to pathology promotes reduction clinical display of heart failure, shows cardioprotective and pulmoprotective effects.
authors.forename: G A
authors.initials: GA
authors.lastname: Ignatenko
authors.forename: I V
authors.initials: IV
authors.lastname: Mukhin
authors.forename: A O
authors.initials: AO
authors.lastname: Faierman
authors.forename: M K
authors.initials: MK
authors.lastname: Pola
authors.forename: G S
authors.initials: GS
authors.lastname: Taktashov
authors.forename: O M
authors.initials: OM
authors.lastname: Goncharov
authors.forename: G S
authors.initials: GS
authors.lastname: Rybalko
authors.forename: N O
authors.initials: NO
authors.lastname: Volodkina
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016022:Case-Control Studies; D002908:Chronic Disease; D019610:Cytoprotection / Q000187:drug effects*; D004359:Drug Therapy, Combination / Q000379:methods*; D005260:Female; D006321:Heart; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006334:Heart Function Tests; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012129:Respiratory Function Tests; D012720:Severity of Illness Index; D014455:Ukraine
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate